Journal Home
Search for

Volume 14, Issue 7, Pages 748-758 (July 2008)


View previous. 7 of 21 View next.

Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival

Daniel Weisdorf1Corresponding Author Informationemail address, Stephen Spellman23, Michael Haagenson3, Mary Horowitz4, Stephanie Lee5, Claudio Anasetti6, Michelle Setterholm2, Rebecca Drexler23, Martin Maiers2, Roberta King2, Dennis Confer23, John Klein4

Received 10 January 2008; accepted 7 April 2008.

Abstract 

The best unrelated donors (URD) for hematopoietic cell transplantation (HCT) are alleles matched at HLA-A, -B, -C, and DRB1. Earlier studies mostly used incomplete or lower resolution HLA typing for analysis of transplant outcome. To understand the impact of incomplete HLA characterization, we analyzed 14,797 URD HCT (1995-2006) using multivariable regression modeling adjusting for factors affecting survival. Of 21 matching cohorts, we identified 3 groups with significantly different outcomes. Well-matched cases had either no identified HLA mismatch and informative data at 4 loci or allele matching at HLA-A, -B, and -DRB1 (n = 7477, 50% of the population). Partially matched pairs had a defined, single-locus mismatch and/or missing HLA data (n = 4962, 34%). Mismatched cases had ≥2 allele or antigen mismatches (n = 2358, 16%). Multivariate adjusted 5-year survival estimates were: well-matched: 54.1 (95% confidence interval), 52.9-55.4), partially matched: 43.7 (42.3-45.2), and mismatched: 33.4 (32.5-36.5), P < .001. A better matched donor yielded 10%-11% better 5-year survival. Importantly, intermediate resolution -A, -B, and -DRB1 alleles matched “6/6 antigen matched” HCT had survival outcomes within the partially matched cohort. We suggest that these proposed HLA subgroupings be used when complete HLA typing is not available. This improved categorization of HLA matching status allows adjustment for donor-recipient HLA compatibility, and can standardize interpretations of prior URD HCT experience.

1 University of Minnesota, Minneapolis, Minnesota

2 National Marrow Donor Program, Minneapolis, Minnesota

3 Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota

4 Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin

5 Fred Hutchinson Cancer Research Center, Seattle, Washington

6 H. Lee Moffitt Cancer Center, Tampa, Florida

Corresponding Author InformationCorrespondence and reprint requests: Daniel Weisdorf, MD, University of Minnesota, Department of Medicine, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455.

PII: S1083-8791(08)00147-X

doi:10.1016/j.bbmt.2008.04.003


View previous. 7 of 21 View next.